Literature DB >> 20856723

ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab-Clinical Implications in Colorectal Cancer.

Roscoe F Morton, Elizabeth H Hammond.   

Abstract

ASCO's Provisional Clinical Opinion alerts oncologists to emerging information from recent clinical trials that can assist them in treatment selection. Evidence suggests that cetuximab and panitumumab are ineffective in patients with KRAS mutations at codon 12 or 13. Thus, patients with colorectal cancer with these mutations should be spared the toxicity and cost of an ineffective therapy.

Entities:  

Year:  2009        PMID： 20856723      PMCID： PMC2790641          DOI： 10.1200/JOP.0924603

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  8 in total

Review 1.  Targeting the epidermal growth factor receptor for cancer therapy.

Authors:  John Mendelsohn
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

2.  Angioplasty and stenting of the cervical carotid artery with embolic protection of the cerebral circulation.

Authors: 
Journal:  Technol Eval Cent Assess Program Exec Summ       Date:  2007-06

3.  KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

Authors:  W De Roock; H Piessevaux; J De Schutter; M Janssens; G De Hertogh; N Personeni; B Biesmans; J-L Van Laethem; M Peeters; Y Humblet; E Van Cutsem; S Tejpar
Journal:  Ann Oncol       Date:  2007-11-12       Impact factor: 32.976

4.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Authors:  Astrid Lièvre; Jean-Baptiste Bachet; Valérie Boige; Anne Cayre; Delphine Le Corre; Emmanuel Buc; Marc Ychou; Olivier Bouché; Bruno Landi; Christophe Louvet; Thierry André; Fréderic Bibeau; Marie-Danièle Diebold; Philippe Rougier; Michel Ducreux; Gorana Tomasic; Jean-François Emile; Frédérique Penault-Llorca; Pierre Laurent-Puig
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

5.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

6.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

7.  Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.

Authors:  F Di Fiore; F Blanchard; F Charbonnier; F Le Pessot; A Lamy; M P Galais; L Bastit; A Killian; R Sesboüé; J J Tuech; A M Queuniet; B Paillot; J C Sabourin; F Michot; P Michel; T Frebourg
Journal:  Br J Cancer       Date:  2007-03-20       Impact factor: 7.640

Review 8.  American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Authors:  Carmen J Allegra; J Milburn Jessup; Mark R Somerfield; Stanley R Hamilton; Elizabeth H Hammond; Daniel F Hayes; Pamela K McAllister; Roscoe F Morton; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544
  8 in total
  15 in total

1.  Medicare's Seasons.

Authors:  John V Cox
Journal:  J Oncol Pract       Date:  2009-03       Impact factor: 3.840

2.  Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients: A Population-based Study.

Authors:  Mary E Charlton; Jordan J Karlitz; Jennifer A Schlichting; Vivien W Chen; Charles F Lynch
Journal:  Am J Clin Oncol       Date:  2017-10       Impact factor: 2.339

3.  Adapting Practice in the Face of New Data.

Authors:  Christopher Stokoe
Journal:  J Oncol Pract       Date:  2009-03       Impact factor: 3.840

Review 4.  Tumor control versus adverse events with targeted anticancer therapies.

Authors:  Dorothy M K Keefe; Emma H Bateman
Journal:  Nat Rev Clin Oncol       Date:  2011-12-20       Impact factor: 66.675

5.  KRAS Testing, Tumor Location, and Survival in Patients With Stage IV Colorectal Cancer: SEER 2010-2013.

Authors:  Mary E Charlton; Amanda R Kahl; Alissa A Greenbaum; Jordan J Karlitz; Chi Lin; Charles F Lynch; Vivien W Chen
Journal:  J Natl Compr Canc Netw       Date:  2017-12       Impact factor: 11.908

6.  Analysis of stage and clinical/prognostic factors for colon and rectal cancer from SEER registries: AJCC and collaborative stage data collection system.

Authors:  Vivien W Chen; Mei-Chin Hsieh; Mary E Charlton; Bernardo A Ruiz; Jordan Karlitz; Sean F Altekruse; Lynn A G Ries; J Milburn Jessup
Journal:  Cancer       Date:  2014-12-01       Impact factor: 6.860

7.  Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer.

Authors:  Jennifer S Lin; Elizabeth M Webber; Caitlyn A Senger; Rebecca S Holmes; Evelyn P Whitlock
Journal:  Am J Cancer Res       Date:  2011-05-15       Impact factor: 6.166

Review 8.  Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions.

Authors:  Veena Shankaran; Jennifer Obel; Al B Benson
Journal:  Oncologist       Date:  2010-02-04

9.  PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.

Authors:  Hsin-Wei Liao; Jung-Mao Hsu; Weiya Xia; Hung-Ling Wang; Ying-Nai Wang; Wei-Chao Chang; Stefan T Arold; Chao-Kai Chou; Pei-Hsiang Tsou; Hirohito Yamaguchi; Yueh-Fu Fang; Hong-Jen Lee; Heng-Huan Lee; Shyh-Kuan Tai; Mhu-Hwa Yang; Maria P Morelli; Malabika Sen; John E Ladbury; Chung-Hsuan Chen; Jennifer R Grandis; Scott Kopetz; Mien-Chie Hung
Journal:  J Clin Invest       Date:  2015-11-16       Impact factor: 14.808

10.  Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Authors:  Julie G Fisher; David Tait; Elizabeth Garrett-Mayer; Susan Halabi; Pam K Mangat; Julian C Schink; Ricardo H Alvarez; Dan Veljovich; Timothy L Cannon; Pamela A Crilley; Theodore Pollock; Carmen J Calfa; Tareq Al Baghdadi; Ramya Thota; Nicole Fleming; Jared A Cotta; Andrew L Rygiel; Sasha L Warren; Richard L Schilsky
Journal:  Target Oncol       Date:  2020-12       Impact factor: 4.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.